Skip to main content

Advertisement

Log in

Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Raynaud’s phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP. Three patients with mixed connective tissue disease and three patients with systemic sclerosis having RP were enrolled. Oral sildenafil, vardenafil, or tadalafil was administered. The fingertip temperature was measured by thermography before and 120 min after administration. To evaluate longer effects, vardenafil was administered daily for 12 weeks; the fingertip temperature was measured by thermography before and 12 weeks after administration. As compared with the pre-administration of sildenafil, vardenafil, and tadalafil, the mean fingertip temperature increased by 2.17, 3.47, and 3.59 °C, respectively, in 120 min. In the 12-week trial with vardenafil in 3 patients, the mean fingertip temperature increased by 3.04, 7.96, and 3.32 °C from baseline in each patient. PDE-5Is significantly increased fingertip temperature within 120 min, and the effect of vardenafil lasted for 12 weeks under daily use. PDE-5Is were safe and would be an effective treatment for RP with CTDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Wollersheim H, VanZwieten PA (1993) Treatment of Raynaud’s phenomenon. Eur Heart J 14(2):147–149

    Article  PubMed  CAS  Google Scholar 

  2. Smith CD, McKendry RJ (1982) Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet 11(8311):1299–1301

    Article  Google Scholar 

  3. Langevitz P, Buskila D, Lee P, Urowitz MB (1989) Treatment of refractory ischemic skin ulcers in patients with Raynaud’s phenomenon with PGE1 infusions. J Rheumatol 16(11):1433–1435

    PubMed  CAS  Google Scholar 

  4. Kirby JD, Lima DR, Dowd PM, Kilfeather S, Turner P (1980) Prostacyclin increases cyclic-nucleotide responsiveness of lymphocytes from patients with systemic sclerosis. Lancet 30(8192):453–454

    Article  Google Scholar 

  5. Dinerman JL, Lowenstein CJ, Snyder SH (1993) Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ Res 73(2):217–222

    Article  PubMed  CAS  Google Scholar 

  6. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75(4):725–748

    PubMed  CAS  Google Scholar 

  7. Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD (1998) Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43(2):163–168

    Article  PubMed  CAS  Google Scholar 

  9. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin CS, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C (2004) Pharmacotherapy for erectile dysfunction. J Sex Med 1(2):128–140

    Article  PubMed  CAS  Google Scholar 

  10. Kamata Y, Nara H, Sato H, Masuyama J-I, Minota S (2005) Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension. Ann Rheum Dis 64(8):1236–1237

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Fries R, Shariat K, von Wilmowsky H, Böhm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112(19):2980–2985

    PubMed  CAS  Google Scholar 

  12. Roustit M, Hellmann M, Cracowski C, Blaise S, Cracowski JL (2012) Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud’s phenomenon. Clin Pharmacol Ther 91(5):813–819

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72(10):1696–1699

    Article  PubMed  CAS  Google Scholar 

  14. Wright PJ (2006) Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 60(8):967–975

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Ethical standard

This study was approved by the ethics committee of the Jichi Medical University, Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasuyuki Kamata.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamata, Y., Minota, S. Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon. Rheumatol Int 34, 1623–1626 (2014). https://doi.org/10.1007/s00296-014-3025-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3025-z

Keywords

Navigation